본문 바로가기
KERD
논문KCI 등재

Advanced heart failure: a contemporary approach

강석민|Kyeong-Hyeon Chun
대한내과학회 (The Korean Association Of Internal Medicine)|2023.07|The Korean Journal of Internal Medicine|제38권 제4호|pp. 471-483

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Heart failureExtracorporeal membrane oxygenationHeart transplantationCardiac resynchronization therapyVentricular assist device
주제분류내과학

초록

Advanced heart failure (HF) is defined as the persistence of severe symptoms despite the use of optimized medical, surgical, and device therapies. These patients require timely advanced treatments, such as heart transplantation or long-term mechanical circulatory support (MCS). Inotropic agents are often used to reduce congestion and increase cardiac output, while renal replacement therapy may be beneficial if necessary. Cardiac resynchronization therapy has clear benefits in patients with HF with reduced ejection fraction, particularly with left bundle branch block (QRS duration > 130 ms). The role of implantable cardioverter-defibrillators in advanced HF patients requires further investigation considering the introduction of novel HF medications. In selected patients with significant secondary mitral regurgitation, transcatheter edge-to-edge repair can help delay heart transplantation or long-term MCS. In later stages, the appropriateness of heart transplantation should be evaluated, and the use of short- or long-term MCS may be considered. A multidisciplinary HF management program is crucial for patients with advanced HF. Recent treatment advances, including drugs, devices, and MCS, have broadened the options available to patients with advanced HF and this trend is expected to continue.

Abstract

Advanced heart failure (HF) is defined as the persistence of severe symptoms despite the use of optimized medical, surgical, and device therapies. These patients require timely advanced treatments, such as heart transplantation or long-term mechanical circulatory support (MCS). Inotropic agents are often used to reduce congestion and increase cardiac output, while renal replacement therapy may be beneficial if necessary. Cardiac resynchronization therapy has clear benefits in patients with HF with reduced ejection fraction, particularly with left bundle branch block (QRS duration > 130 ms). The role of implantable cardioverter-defibrillators in advanced HF patients requires further investigation considering the introduction of novel HF medications. In selected patients with significant secondary mitral regurgitation, transcatheter edge-to-edge repair can help delay heart transplantation or long-term MCS. In later stages, the appropriateness of heart transplantation should be evaluated, and the use of short- or long-term MCS may be considered. A multidisciplinary HF management program is crucial for patients with advanced HF. Recent treatment advances, including drugs, devices, and MCS, have broadened the options available to patients with advanced HF and this trend is expected to continue.

참고문헌 (91)

  1. Benjamin EJ, "Heart disease and stroke statistics-2018 update: a report from the American Heart Association", Circulation, 137, pp.e67~e492 (2018)
  2. Sato N, "Epidemiology of Heart Failure in Asia", Heart Fail Clin, 11, pp.573~579 (2015)
  3. Park Jin Joo, "Heart Failure Statistics in Korea, 2020: A Report from the Korean Society of Heart Failure", International Journal of Heart Failure, 3(4), pp.224~ (2021), 대한심부전학회[DOI]
  4. Jae Yeong Cho, "Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis", Korean Circulation Journal, 53(4), pp.195~216 (2023), 대한심장학회[DOI]
  5. Ammar KA, "Prevalence and prognostic significance of heart failure stages : application of the American College of Cardiology", American Heart Association heart failure staging criteria in the community, 2007, pp.115, 1563~1570
  6. Xanthakis V, "Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community", JACC Heart Fail, 4, pp.808~815 (2016)
  7. Go AS, "Heart disease and stroke statistics--2014 update:a report from the American Heart Association", Circulation, 129, pp.e28~e292 (2014)
  8. Nohria A, "Medical management of advanced heart failure", JAMA, 287, pp.628~640 (2002)
  9. Crespo-Leiro MG, "Advanced heart failure : a position statement of the Heart Failure Association of the European Society of Cardiology", Eur J Heart Fail, 20, pp.1505~1535 (2018)
  10. McDonagh TA, "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42, pp.3599~3726 (2021)
  11. Heidenreich PA, "2022 AHA", ACC, American Heart Association Joint Committee on clinical practice guidelines, pp.Circulation, 2022[DOI]
  12. Fang JC, "Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee", J Card Fail, 21, pp.519~534 (2015)
  13. Stevenson LW, "INTERMACS profiles of advanced heart failure : the current picture", J Heart Lung Transplant, 28, pp.535~541 (2009)
  14. van Diepen S, "Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association", Circulation, 136, pp.e232~e268 (2017)
  15. Barge-Caballero E, "Preoperative INTERMACS profiles determine postoperative outcomes in critically ill patients undergoing emergency heart transplantation : analysis of the Spanish National Heart Transplant Registry", Circ Heart Fail, 6, pp.763~772 (2013)
  16. Goldstein DJ, "Third Annual Report from the ISHLT Mechanically Assisted Circulatory Support Registry : a comparison of centrifugal and axial continuous-flow left ventricular assist devices", J Heart Lung Transplant, 38, pp.352~363 (2019)
  17. Kittleson MM, "INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL Registry", J Heart Lung Transplant, 39, pp.16~26 (2020)
  18. Youn Jong-Chan, "Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment", International Journal of Heart Failure, 5(2), pp.66~81 (2023), 대한심부전학회[DOI]
  19. Maack C, "Treatments targeting inotropy", Eur Heart J, 40, pp.3626~3644 (2019)
  20. Ahmad T, "Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials", Eur J Heart Fail, 21, pp.1064~1078 (2019)
  21. Levy B, "Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study", Crit Care Med, 39, pp.450~455 (2011)
  22. Levy B, "Epinephrine Versus norepinephrine for cardiogenic shock after acute myocardial infarction", J Am Coll Cardiol, 72, pp.173~182 (2018)
  23. De Backer D, "Comparison of dopamine and norepinephrine in the treatment of shock", N Engl J Med, 362, pp.779~789 (2010)
  24. Mathew R, "Milrinone as compared with dobutamine in the treatment of cardiogenic shock", N Engl J Med, 385, pp.516~525 (2021)
  25. Mathew R, "Efficacy of milrinone and dobutamine in low cardiac output states : systematic review and meta-analysis", Clin Invest Med, 42, pp.E26~E32 (2019)
  26. Mebazaa A, "Levosimendan vs. dobutamine : outcomes for acute heart failure patients on beta-blockers in SURVIVE", Eur J Heart Fail, 11, pp.304~311 (2009)
  27. Silvetti S, "Repeated or intermittent levosimendan treatment in advanced heart failure : an updated meta-analysis", Int J Cardiol, 202, pp.138~143 (2016)
  28. Silvetti S, "Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients : a meta-analysis of randomized trials", ESC Heart Fail, 4, pp.595~604 (2017)
  29. Hershberger RE, "Care processes and clinical outcomes of continuous outpatient support with inotropes(COSI)in patients with refractory endstage heart failure", J Card Fail, 9, pp.180~187 (2003)
  30. Sawamura Akinori, "Clinical Impact of Worsening Renal Function in Elderly Patients with Acute Decompensated Heart Failure", International Journal of Heart Failure, 3(2), pp.128~ (2021), 대한심부전학회[DOI]
  31. Mullens W, "The use of diuretics in heart failure with congestion-a position statement from the Heart Failure Association of the European Society of Cardiology", Eur J Heart Fail, 21, pp.137~155 (2019)
  32. Felker GM, "Diuretic strategies in patients with acute decompensated heart failure", N Engl J Med, 364, pp.797~805 (2011)
  33. Repasos E, "Intermittent renal replacement therapy for end stage drug refractory heart failure", Int J Cardiol, 183, pp.24~26 (2015)
  34. Herweg B, "When is it too late for cardiac resynchronization therapy?", Pacing Clin Electrophysiol, 31, pp.525~528 (2008)
  35. Bristow MR, "Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure", N Engl J Med, 350, pp.2140~2450 (2004)
  36. Lindenfeld J, "Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure", Circulation, 115, pp.204~212 (2007)
  37. Carluccio E, "Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony", JACC Cardiovasc Imaging, 4, pp.1067~1076 (2011)
  38. Herweg B, "The evolution of cardiac resynchronization therapy and an introduction to conduction system pacing : a conceptual review", Europace, 23, pp.496~510 (2021)
  39. Fu Y, "Left bundle branch area pacing : a promising modality for cardiac resynchronization therapy", Front Cardiovasc Med, 9, pp.901046~ (2022)
  40. Huang W, "Pursue physiological pacing therapy : a better understanding of left bundle branch pacing and left ventricular septal myocardial pacing", Heart Rhythm, 18, pp.1290~1291 (2021)
  41. Curila K, "Left bundle branch pacing compared to left ventricular septal myocardial pacing increases interventricular dyssynchrony but accelerates left ventricular lateral wall depolarization", Heart Rhythm, 18, pp.1281~1289 (2021)
  42. Jastrzębski M, "Left bundle branch-optimized cardiac resynchronization therapy(LOTCRT) : Results from an international LBBAP collaborative study group", Heart Rhythm, 19, pp.13~21 (2022)
  43. Moss AJ, "Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction", N Engl J Med, 346, pp.877~883 (2002)
  44. Bardy GH, "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", N Engl J Med, 352, pp.225~237 (2005)
  45. Køber L, "Defibrillator Implantation in patients with nonischemic systolic heart failure", N Engl J Med, 375, pp.1221~1230 (2016)
  46. Packer M, "New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation", JAMA Cardiol, 5, pp.469~475 (2020)
  47. Gaasch WH, "Secondary mitral regurgitation(part 1) : volumetric quantification and analysis", Heart, 104, pp.634~638 (2018)
  48. Michler RE, "CTSN. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation", N Engl J Med, 374, pp.1932~1941 (2016)
  49. Bartko PE, "Disproportionate functional mitral regurgitation : advancing a conceptual framework to clinical practice", JACC Cardiovasc Imaging, 12, pp.2088~2090 (2019)
  50. Ningyan Wong, "Percutaneous Edge-to-Edge Mitral Valve Repair for Functional Mitral Regurgitation", International Journal of Heart Failure, 4(2), pp.55~ (2022), 대한심부전학회[DOI]
  51. Godino C, "MitraClip in secondary mitral regurgitation as a bridge to heart transplantation : 1-year outcomes from the International MitraBridge Registry", J Heart Lung Transplant, 39, pp.1353~1362 (2020)
  52. Kar B, "The percutaneous ventricular assist device in severe refractory cardiogenic shock", J Am Coll Cardiol, 57, pp.688~696 (2011)
  53. Smedira NG, "Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure : survival at five years", J Thorac Cardiovasc Surg, 122, pp.92~102 (2001)
  54. Cheng JM, "Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock : a meta-analysis of controlled trials", Eur Heart J, 30, pp.2102~2108 (2009)
  55. Alba AC, "Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation", J Heart Lung Transplant, 28, pp.827~833 (2009)
  56. Lima B, "Effectiveness and safety of the impella 5. 0 as a bridge to cardiac transplantation or durable left ventricular assist device", Am J Cardiol, 117, pp.1622~1628 (2016)
  57. Kirklin JK, "The Fourth INTERMACS Annual Report : 4, 000 implants and counting", J Heart Lung Transplant, 31, pp.117~126 (2012)
  58. Barge-Caballero E, "Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation : a nationwide Spanish registry", Eur J Heart Fail, 20, pp.178~186 (2018)
  59. Thiele H, "Intraaortic balloon support for myocardial infarction with cardiogenic shock", N Engl J Med, 367, pp.1287~1296 (2012)
  60. Thiele H, "Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II):final 12 month results of a randomised, open-label trial", Lancet, 382, pp.1638~1645 (2013)
  61. Sandhu A, "Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention : insights from the National Cardiovascular Data Registry", Circulation, 132, pp.1243~1251 (2015)
  62. 김인철, "The Past, Present and Future of Heart Transplantation", Korean Circulation Journal, 48(7), pp.565~590 (2018), 대한심장학회[DOI]
  63. Kawashima D, "Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation", ASAIO J, 57, pp.169~176 (2011)
  64. Koeckert MS, "Impella LP 2. 5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support", J Card Surg, 26, pp.666~668 (2011)
  65. Rao P, "Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest", Circ Heart Fail, 11, pp.e004905~ (2018)
  66. Biscotti M, "The"sport model" : extracorporeal membrane oxygenation using the subclavian artery", Ann Thorac Surg, 98, pp.1487~1489 (2014)
  67. Chicotka S, "The"Central Sport Model" : extracorporeal membrane oxygenation using the innominate artery for smaller patients as bridge to lung transplantation", ASAIO J, 63, pp.e39~e44 (2017)
  68. Rao P, "Ambulatory central VA-ECMO with biventricular decompression for acute cardiogenic shock", Catheter Cardiovasc Interv, 92, pp.1002~1004 (2018)
  69. Mehra MR, "A fully magnetically levitated left ventricular assist device - final report", N Engl J Med, 380, pp.1618~1627 (2019)
  70. Molina EJ, "The Society of Thoracic Surgeons Intermacs 2020 annual report", Ann Thorac Surg, 111, pp.778~792 (2021)
  71. Slaughter MS, "Advanced heart failure treated with continuous-flow left ventricular assist device", N Engl J Med, 361, pp.2241~2251 (2009)
  72. Rogers JG, "Intrapericardial left ventricular assist device for advanced heart failure", N Engl J Med, 376, pp.451~460 (2017)
  73. Frazier OH, "Left Ventricular Assist System. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation", J Thorac Cardiovasc Surg, 122, pp.1186~1195 (2001)
  74. Yoonjee Park, "Clinical outcome in patients with end-stage heart failure who underwent continuous-flow left ventricular assist devices in a single center", The Korean Journal of Internal Medicine, 37(2), pp.340~349 (2022), 대한내과학회[DOI]
  75. Kim IC, "Donor heart utilization in Korea", Int J Heart Fail, 2, pp.254~263 (2020)
  76. Starling RC, "Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results", JACC Heart Fail, 5, pp.518~527 (2017)
  77. Khush KK, "The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match", J Heart Lung Transplant, 38, pp.1056~1066 (2019)
  78. Colvin M, "OPTN", SRTR 2018 annual data report: heart, 2020, pp.20(Suppl s1), 340~426
  79. Hayward Christopher, "Cardiac Allograft Injuries: A Review of Approaches to a Common Dilemma, With Emphasis on Emerging Techniques", International Journal of Heart Failure, 4(3), pp.123~ (2022), 대한심부전학회[DOI]
  80. Yoon M, "Impact of predicted heart massbased size matching on survival after heart transplantation in Korea : Analysis of the Korean Organ Transplant Registry", J Heart Lung Transplant, 41, pp.1751~1760 (2022)
  81. Lee JM, "Coronary microcirculatory dysfunction and acute cellular rejection after heart transplantation", Circulation, 144, pp.1459~1472 (2021)
  82. Youn JC, "Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation", Front Cardiovasc Med, 9, pp.939275~ (2022)
  83. Youn JC, "Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy", Am J Transplant, 22, pp.2942~2950 (2022)
  84. Mehra MR, "The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update", J Heart Lung Transplant, 35, pp.1~23 (2016)
  85. Kittleson MM, "Hurst’s The Heart" (2017), McGraw-Hill Education
  86. Wever-Pinzon O, "Team-based care for advanced heart failure", Heart Fail Clin, 11, pp.467~477 (2015)
  87. Matsue Y, "Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure : the FRAGILE-HF cohort study", Eur J Heart Fail, 22, pp.2112~2119 (2020)
  88. Dunlay SM, "Frailty and outcomes after implantation of left ventricular assist device as destination therapy", J Heart Lung Transplant, 33, pp.359~365 (2014)
  89. Chun KH, "Cardiac rehabilitation in heart failure", Int J Heart Fail, 3, pp.1~14 (2020)
  90. Ameri P, "Cancer diagnosis in patients with heart failure:epidemiology, clinical implications and gaps in knowledge", Eur J Heart Fail, 20, pp.879~887 (2018)
  91. Ju-Hee Lee, "End-of-Life Care for End-stage Heart Failure Patients", Korean Circulation Journal, 52(9), pp.659~679 (2022), 대한심장학회[DOI]

관련 논문AI추천

Update on heart failure management and future directions박명수, 윤종찬, 최홍미대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제1호Current status of heart failure: global and KoreaDong-Ju Choi, Jin Joo Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호Heart failure with preserved ejection fraction: insights from recent clinical researchesMi-Na Kim, Seong-Mi Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fractionJin-Oh Choi, Minjung Bak대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제5호How to tackle congestion in acute heart failurePieter Martens, Wilfried Mullens대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제3호Clinical Implication of Mechanical Dyssynchrony in Heart FailureCheuk-Man Yu, Qing Zhang한국심초음파학회 · Journal of Cardiovascular Imaging2012 · 제20권 제3호

이 간행물의 다른 논문 (18건)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection김태호pp. 451-453Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection신현필pp. 454-455Role of echocardiography in acute pulmonary embolismJae-Hyeong Park, Jin Kyung Ohpp. 456-470Association between eupatilin and reduction in small bowel bleeding in aspirin users and aspirin plus acid suppressant usersHyun Seok Lee, Hyun Jung Ahn, 오동준, 남지형, Yun Jeong Limpp. 484-492Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradicationDong Wook Lee, Su Youn Nam, Seong Woo Jeon, Yong Hwan Kwon, Ji Hey Park, Hui Jin Baepp. 493-503
원문 보기